Orvar™ Autoantigen Discovery Technology
Using conventional methods, it would be necessary to screen every single human protein, splice variant, neoantigen or microbial antigen to discover the total repertoire of autoantigens within a disease.
By using the Orvar™ Autoantigen Discovery Technology, the identity of all the autoantigens and antigens that make up the Autoproteome™ can be discovered. The Autoproteome™ is defined as the totality of autoantigens and antigens within a human at any one time the individual may or may not have the disease.
Orvar™ identifies all possible autoantigens and antigens within a human at a given time which are associated with a disease.
Once the Autoproteome™ is identified, we then use our patented KREX™ technology to clone, express and attach every single autoantigen or antigen on to a Sengenics protein array. This customised protein array then serves as a validated, true positive antigen and autoantigen library which is disease-specific. Applications for this protein array include the discovery of autoantibodies for characterisation of diseases either as biomarkers for early diagnostics, protective autoantibodies or intra-disease stratification.
Orvar™ Case Study
- Sample type:
- Plasma from Colorectal cancer and healthy normal individuals
- Tissue from Colorectal cancer individuals (cancer and adjacent normal tissue)
- Sengenics KREX CT100+ microarray
- Orvar™ Autoproteome™ Discovery technology
Breakdown of Selected/Identified Antigens
- The Orvar™ technology identified a total of 28 unique autoantigens (Figure 2) which had corresponding autoantibodies present in Colorectal cancer patients;
- This Orvar™ Colorectal library also led to the discovery of homologues to the antigens eliciting high autoantibody responses on KREX microarrays. These homologues may contain overlapping surface epitopes reactive to these autoantibodies;
- As all antigens immobilised onto the KREX microarrays are present as wild-type forms, the unique antigens on Orvar™ which are also on KREX microarrays suggests detection of mutated forms of these antigens using the Orvar™ technology.
© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361